Clinical Scorecard: Metagenomic Analysis of Gut Microbiota in Patients with Interstitial Lung Disease Linked to Rheumatoid Arthritis: Taxonomic Changes and Clinical Associations

At a Glance

Key Highlights

• Exploratory analysis revealed enrichment of Escherichia/Shigella in RA-ILD patients.
• Depletion of Roseburia and Ruminococcus observed in RA-ILD compared to RA-non-ILD.
• Pro-inflammatory genera correlated positively with disease activity.
• Butyrate-producing genera correlated negatively with disease activity.
• Random forest classification identified specific taxa as discriminators between groups.

Guideline-Based Recommendations

Diagnosis

• Limited diagnostic biomarkers for RA-ILD.

Management

• Further validation of identified taxa as candidate biomarkers in larger cohorts.

Monitoring & Follow-up

• Correlation of gut microbiota changes with systemic inflammation.

Risks

• Potential for gut microbiota alterations to influence RA-ILD pathogenesis.

Patient & Prescribing Data

41 participants including RA-ILD patients, RA-non-ILD patients, and healthy controls.

Specific gut microbial alterations may inform future therapeutic strategies.

Clinical Best Practices

• Consider gut microbiota profiling in RA-ILD research.
• Monitor systemic inflammation in relation to gut microbiota changes.

Related Resources & Content